Pesquisa | BVS Doenças Infecciosas e Parasitárias

1.

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.

Zeitlinger, Markus; Bauer, Martin; Reindl-Schwaighofer, Roman; Stoekenbroek, Robert M; Lambert, Gilles; Berger-Sieczkowski, Evelyn; Lagler, Heimo; Oesterreicher, Zoe; Wulkersdorfer, Beatrix; Lührs, Petra; Galabova, Gergana; Schwenke, Carsten; Mader, Robert M; Medori, Rossella; Landlinger, Christine; Kutzelnigg, Alexandra; Staffler, Günther.

Eur J Clin Pharmacol ; 77(10): 1473-1484, 2021 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-33969434

2.

A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.

Meissner, Wassilios G; Traon, Anne Pavy-Le; Foubert-Samier, Alexandra; Galabova, Gergana; Galitzky, Monique; Kutzelnigg, Alexandra; Laurens, Brice; Lührs, Petra; Medori, Rossella; Péran, Patrice; Sabatini, Umberto; Vergnet, Sylvain; Volc, Dieter; Poewe, Werner; Schneeberger, Achim; Staffler, Günther; Rascol, Olivier.

Mov Disord ; 35(11): 1957-1965, 2020 11.

Artigo em Inglês | MEDLINE | ID: mdl-32882100

3.

Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET.

Vanicek, Thomas; Kutzelnigg, Alexandra; Philippe, Cecile; Sigurdardottir, Helen L; James, Gregory M; Hahn, Andreas; Kranz, Georg S; Höflich, Anna; Kautzky, Alexander; Traub-Weidinger, Tatjana; Hacker, Marcus; Wadsak, Wolfgang; Mitterhauser, Markus; Kasper, Siegfried; Lanzenberger, Rupert.

Hum Brain Mapp ; 38(2): 792-802, 2017 02.

Artigo em Inglês | MEDLINE | ID: mdl-27770470

4.

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron.

Haider, Lukas; Simeonidou, Constantina; Steinberger, Günther; Hametner, Simon; Grigoriadis, Nikolaos; Deretzi, Georgia; Kovacs, Gabor G; Kutzelnigg, Alexandra; Lassmann, Hans; Frischer, Josa M.

J Neurol Neurosurg Psychiatry ; 85(12): 1386-95, 2014 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-24899728

5.

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.

Poewe, Werner; Volc, Dieter; Seppi, Klaus; Medori, Rossella; Lührs, Petra; Kutzelnigg, Alexandra; Djamshidian, Atbin; Thun-Hohenstein, Caroline; Meissner, Wassilios G; Rascol, Olivier; Schneeberger, Achim; Staffler, Günther; Poewe, Werner; Seppi, Klaus; Djamshidian, Atbin; deMarzi, Roberto; Heim, Beatrice; Mangesius, Stephanie; Stolz, Raphaela; Wachowicz, Katarzyna; Volc, Dieter; Thun-Hohenstein, Caroline; Riha, Constanze; Schneeberger, Achim; Bürger, Vera; Galabova, Gergana.

J Parkinsons Dis ; 11(3): 1079-1089, 2021.

Artigo em Inglês | MEDLINE | ID: mdl-34092654

6.

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.

Volc, Dieter; Poewe, Werner; Kutzelnigg, Alexandra; Lührs, Petra; Thun-Hohenstein, Caroline; Schneeberger, Achim; Galabova, Gergana; Majbour, Nour; Vaikath, Nishant; El-Agnaf, Omar; Winter, Dorian; Mihailovska, Eva; Mairhofer, Andreas; Schwenke, Carsten; Staffler, Günther; Medori, Rossella.

Lancet Neurol ; 19(7): 591-600, 2020 07.

Artigo em Inglês | MEDLINE | ID: mdl-32562684

7.

Multiple sclerosis and Alzheimer's disease.

Dal Bianco, Assunta; Bradl, Monika; Frischer, Josa; Kutzelnigg, Alexandra; Jellinger, Kurt; Lassmann, Hans.

Ann Neurol ; 63(2): 174-83, 2008 Feb.

Artigo em Inglês | MEDLINE | ID: mdl-17924575

8.

Widespread demyelination in the cerebellar cortex in multiple sclerosis.

Kutzelnigg, Alexandra; Faber-Rod, Jens C; Bauer, Jan; Lucchinetti, Claudia F; Sorensen, Per S; Laursen, Henning; Stadelmann, Christine; Brück, Wolfgang; Rauschka, Helmut; Schmidbauer, Manfred; Lassmann, Hans.

Brain Pathol ; 17(1): 38-44, 2007 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-17493036

9.

Remyelination is extensive in a subset of multiple sclerosis patients.

Patrikios, Peter; Stadelmann, Christine; Kutzelnigg, Alexandra; Rauschka, Helmut; Schmidbauer, Manfred; Laursen, Henning; Sorensen, Per Soelberg; Brück, Wolfgang; Lucchinetti, Claudia; Lassmann, Hans.

Brain ; 129(Pt 12): 3165-72, 2006 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-16921173

10.

Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis.

Hochmeister, Sonja; Grundtner, Roland; Bauer, Jan; Engelhardt, Britta; Lyck, Ruth; Gordon, Grace; Korosec, Thomas; Kutzelnigg, Alexandra; Berger, Johannes J; Bradl, Monika; Bittner, Reginald E; Lassmann, Hans.

J Neuropathol Exp Neurol ; 65(9): 855-65, 2006 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-16957579

11.

Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits?

Kutzelnigg, Alexandra; Lassmann, Hans.

J Neurol Sci ; 245(1-2): 123-6, 2006 Jun 15.

Artigo em Inglês | MEDLINE | ID: mdl-16650874

12.

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

Kutzelnigg, Alexandra; Lucchinetti, Claudia F; Stadelmann, Christine; Brück, Wolfgang; Rauschka, Helmut; Bergmann, Markus; Schmidbauer, Manfred; Parisi, Joseph E; Lassmann, Hans.

Brain ; 128(Pt 11): 2705-12, 2005 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-16230320

13.

Cortical lesions and brain atrophy in MS.

Kutzelnigg, Alexandra; Lassmann, Hans.

J Neurol Sci ; 233(1-2): 55-9, 2005 Jun 15.

Artigo em Inglês | MEDLINE | ID: mdl-15893328

14.

[Significance of Ginkgo biloba extract in dementia]. / Stellenwert von Ginkgo-biloba-Extrakt bei Demenzerkrankungen.

Kasper, Siegfried; Winkler, Dietmar; Kutzelnigg, Alexandra.

Pharm Unserer Zeit ; 38(5): 424-30, 2009.

Artigo em Alemão | MEDLINE | ID: mdl-19711318

15.

Pathology of multiple sclerosis and related inflammatory demyelinating diseases.

Kutzelnigg, Alexandra; Lassmann, Hans.

Handb Clin Neurol ; 122: 15-58, 2014.

Artigo em Inglês | MEDLINE | ID: mdl-24507512

16.

Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study.

Kutzelnigg, Alexandra; Kopeinig, Martin; Chen, Chih-Ken; Fábián, Agnes; Pujol-Luna, María Gloria; Shin, Young-Chul; Treuer, Tamás; D'yachkova, Yulia; Deix, Claudia; Kasper, Siegfried; Doby, Dagmar.

Int J Bipolar Disord ; 2(1): 13, 2014 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-25360398

17.

The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography.

Vanicek, Thomas; Spies, Marie; Rami-Mark, Christina; Savli, Markus; Höflich, Anna; Kranz, Georg S; Hahn, Andreas; Kutzelnigg, Alexandra; Traub-Weidinger, Tatjana; Mitterhauser, Markus; Wadsak, Wolfgang; Hacker, Marcus; Volkow, Nora D; Kasper, Siegfried; Lanzenberger, Rupert.

JAMA Psychiatry ; 71(12): 1340-1349, 2014 Dec 01.

Artigo em Inglês | MEDLINE | ID: mdl-25338091

18.

Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines.

Ramos-Quiroga, Josep Antoni; Montoya, Alonso; Kutzelnigg, Alexandra; Deberdt, Walter; Sobanski, Esther.

Curr Med Res Opin ; 29(9): 1093-104, 2013 Sep.

Artigo em Inglês | MEDLINE | ID: mdl-23742051

19.

Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine.

Upadhyaya, Himanshu; Adler, Lenard A; Casas, Miguel; Kutzelnigg, Alexandra; Williams, David; Tanaka, Yoko; Arsenault, Jody; Escobar, Rodrigo; Allen, Albert J.

Child Adolesc Psychiatry Ment Health ; 7(1): 14, 2013 May 06.

Artigo em Inglês | MEDLINE | ID: mdl-23648011

20.

Improvement of the noradrenergic symptom cluster following treatment with milnacipran.

Kasper, Siegfried; Meshkat, Diana; Kutzelnigg, Alexandra.

Neuropsychiatr Dis Treat ; 7(Suppl 1): 21-7, 2011.

Artigo em Inglês | MEDLINE | ID: mdl-21750625

BVS Doenças Infecciosas e Parasitárias

Informação e Conhecimento para a Saúde

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.

A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.

Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET.

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron.

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.

Multiple sclerosis and Alzheimer's disease.

Widespread demyelination in the cerebellar cortex in multiple sclerosis.

Remyelination is extensive in a subset of multiple sclerosis patients.

Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis.

Cortical demyelination in multiple sclerosis: a substrate for cognitive deficits?

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

Cortical lesions and brain atrophy in MS.

[Significance of Ginkgo biloba extract in dementia]. / Stellenwert von Ginkgo-biloba-Extrakt bei Demenzerkrankungen.

Pathology of multiple sclerosis and related inflammatory demyelinating diseases.

Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study.

The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography.

Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines.

Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine.

Improvement of the noradrenergic symptom cluster following treatment with milnacipran.